H. Märki

发表

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

B. Kuhn, J. Benz, A. Ruf, 2009, Bioorganic & medicinal chemistry letters.

Structure-based design of indole propionic acids as novel PPARα/γ co-agonists

Hans Peter Märki, Jörg Benz, Bernd Kuhn, 2006 .

Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?

F. Winkler, A. D'arcy, C. Oefner, 1999, Chemistry & biology.

Substituted piperidines--highly potent renin inhibitors due to induced fit adaptation of the active site.

C. Oefner, A. Binggeli, H. Märki, 1999, Bioorganic & medicinal chemistry letters.

Piperidine-renin inhibitors compounds with improved physicochemical properties.

M. Kansy, C. Oefner, A. Binggeli, 1999, Bioorganic & medicinal chemistry letters.

Synthesis of annulated pyridines as inhibitors of aldosterone synthase (CYP11B2).

Rainer E. Martin, B. Kuhn, A. Mayweg, 2016, Organic & biomolecular chemistry.

Discovery of 4-Aryl-5,6,7,8-tetrahydroisoquinolines as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors: In Vivo Evaluation in Rodents and Cynomolgus Monkeys.

Rainer E. Martin, B. Kuhn, A. Kuglstatter, 2015, Journal of medicinal chemistry.

Piperidine renin inhibitors: from leads to drug candidates.

T Hartung, F C Luft, M. Kansy, 2001, Farmaco.

A new class of inhibitors for the malarial aspartic protease plasmepsin II based on a central 11-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene scaffold

F. Diederich, H. Märki, A. Dorn, 2003 .

Development of a New Class of Inhibitors for the Malarial Aspartic Protease Plasmepsin II Based on a Central 7‐Azabicyclo[2.2.1]heptane Scaffold

F. Diederich, H. Märki, P. Seiler, 2003 .

Identification of the active‐site serine in human pancreatic lipase by chemical modification with tetrahydrolipstatin

P. Hadváry, H. Märki, Q. Lüthi-Peng, 1992, FEBS letters.

Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors.

B. Kuhn, A. Kuglstatter, S. Müller, 2020, Journal of medicinal chemistry.

Design and Biological Evaluation of Novel, Balanced Dual PPARα/γ Agonists

Armin Ruf, Jörg Benz, Daniel Schlatter, 2009, ChemMedChem.

A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-γ (PPARγ) Recruits PPARγ-Coactivator-1α, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro

Armin Ruf, Hans Peter Märki, Jörg Benz, 2006 .

Oxidosqualene cyclase (OSC) inhibitors for the treatment of dyslipidemia

T. Schulz-Gasch, M. Kansy, R. Thoma, 2005 .

De Novo Design, Synthesis, and In Vitro Evaluation of a New Class of Nonpeptidic Inhibitors of the Malarial Enzyme Plasmepsin II

F. Diederich, H. Märki, A. Dorn, 2002, Chembiochem : a European journal of chemical biology.

A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.

Armin Ruf, Hans Peter Märki, Jörg Benz, 2006, Molecular endocrinology.

Optically Pure Isoproterenol Analogues With Side Chains Containing an Amide Bond: Synthesis and biological properties

K. Melmon, H. Märki, H. Ramuz, 1988 .

Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.

B. Kuhn, J. Benz, H. Hilpert, 2006, Bioorganic & Medicinal Chemistry Letters.

In vitro pharmacological properties of a series of isoprenaline derivatives.

K. Melmon, W. Burkard, H. Märki, 1989, Arzneimittel-Forschung.

Frontiers in Medicinal Chemistry – Joint German-Swiss Meeting on Medicinal Chemistry: Heidelberg, Germany, March 15–18, 2009

W. Neidhart, H. Märki, P. Mohr, 2009 .

A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor- (cid:1) (PPAR (cid:1) ) Recruits PPAR (cid:1) -Coactivator-1 (cid:2) , Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro

B. Kuhn, A. Rufer, B. Gsell, 2006 .